2024-10-19

TenNor Presents TNP-2092 Results at IDWeek 2024 Annual Meeting

October 18, 2024, Los Angels USA – Today, TenNor Therapeutics and its partners presented a series of research results on TNP-2092 (rifaquizinone) for the treatment of implantable medical device infections at the IDWeek 2024.

 

TenNor and its partners submitted a total of 8 abstracts on TNP-2092 to the conference and all of them were accepted. These studies covered the efficacy study of TNP-2092 administered by intra-articular injection in an animal model of artificial joint infection, the pharmacokinetics and safety study of TNP-2092 administered by intra-articular injection in rats and dogs, the absorption, metabolism and excretion study of [C14]-TNP-2092 in healthy volunteers, the pharmacokinetics and safety bridging study of TNP-2092 in healthy Chinese volunteers, the joint tissue drug distribution and pharmacokinetics study of TNP-2092 in joint replacement patients, and the safety, efficacy and pharmacokinetics study of TNP-2092 in patients with acute bacterial skin and skin structure infections.

 

TenNor collaborators participating in the presentation include Rothman Orthopedic Institute, Huashan Hospital Affiliated to Fudan University, Velocity Clinical Research, Allucent Clinical Research, Pharmaron, WuXi AppTec, University of North Texas Health Science Center and Zhongnan Hospital of Wuhan University.

 

TNP-2092 for treating implantable medical device infections received significant attention from clinicians and researchers attending the conference.

 

 

About TenNor Therapeutics

TenNor Therapeutics is a clinical-stage company specialized in the discovery and development of differentiated new drug products in diseases associated with bacterial infection and metabolism. TenNor possesses a unique multi-targeting drug conjugate technology platform and a strong new drug development pipeline with global IP protection. Several products are currently in late-stage of clinical development targeting H. pylori infection, implanted medical device infections, hepatic encephalopathy and irritable bowel syndrome with diarrhea. The company is committed to address the unmet needs in the disease area and provide safe and effective therapies for patients in China and around the world.

For more information, please visit: www.tennorx.com